Optimizing initial vancomycin dosing in burn patients

Burns

Volumn 37, Issue 3, 2011, Pages 406-414

  Elligsen, Marion ^a,b   Walker, Sandra A N ^a,b   Walker, Scott E ^a,b   Simor, Andrew ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Burn; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BURN; BURN PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BURNS; CLINICAL PROTOCOLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; VANCOMYCIN; WOUND INFECTION; YOUNG ADULT;

EID: 79952897863     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2010.06.005     Document Type: Article

References (27)

1. Fitzwater J, Purdue GF, Hunt JL, O'Keefe GE. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma 2003;54(5):959-66. (Pubitemid 36758807)
2. Kollef M, Sherman G, Ward S, Fraser V. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74. (Pubitemid 29083057)
3. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
4. Tunkel A, Hartman B, Kaplan S, Kaufman B, Roos K, Scheld W, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84. (Pubitemid 39458512)
5. Rybak M, Lomaetro B, Rotschafer J, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
6. Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434.
7. Moise P, Forrest A, Bhavnani S, Birmingham M, Schentag J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomcyin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57:S4-9.
8. Moise-Broder P, Forrest A, Birmingham M, Schentag J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylcoccus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42. (Pubitemid 39447034)
9. Charles P, Ward P, Johnson P, Howden B, Grayson M. Clinical features associated with bacteremia due to heterogenous vancomycin intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51. (Pubitemid 38200128)
10. Geisel R, Schmitz FJ, Fluit AC, Labischinski H. Emergence, mechanism and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2001;20:685-97. (Pubitemid 33020779)
11. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6. (Pubitemid 27341646)
12. Webster D, Rennie R, Brosnikoff C, Chui L, Brown C. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada. Diagn Microbiol Infect Dis 2007;57:177-81. (Pubitemid 46135865)
13. Lodise T, Patel N, Lomaestro B, Rodvold K, Drusano G. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;507-14.
14. Rybak M, Albrecht L, Berman J, Warbasse L, Svensson C. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-5. (Pubitemid 20142400)
15. Garrelts J, Peterie J. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44:9-13.
16. Rutledge R, Lentz C, Fakhry S, Hunt J. Appropriate use of the Glasgow coma scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor Scores. J Trauma 1996;41(3):514-22. (Pubitemid 26318084)
17. Meredith W, Rutledge R, Fakhry SM, Emery S, Kromhout-Schiro S. The conundrum of the Glasgow coma scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores. J Trauma 1998;44(5):839-45. (Pubitemid 28233031)
18. Zukufa H, Solem L, Rodvold K, Crossley K, Fischer JH, Rotschafer JC. The influence of serum albumin and α1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 1989;10(5):425-8. (Pubitemid 19250620)
19. Brater CD, Bawdon RE, Anderson SA, Purdue GF, Hunt JL. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986;39:631-4. (Pubitemid 16097301)
20. Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29(1):15-28.
21. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990;18(2):118-30. (Pubitemid 20104031)
22. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22(3):391-4. (Pubitemid 13241697)
23. Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet P. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int J Antimicrob Agents 2008;31:537-9.
24. Conil JM, Favarel H, Laguerre A, Brouchet A, Chabanon G, Cazal L, et al. [Continuous administration of vancomycin in patients with severe burns]. Presse Med 1994;23(34):1554-8.
25. Bailie GR, Ackerman BH, Fischer J, Solem LD, Rotschafer JC. Increased vancomycin dosage requirements in young burn patients. J Burn Care Rehabil 1984;5(5):376-8. (Pubitemid 15214467)
26. Lodise T, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;1330-6. (Pubitemid 351521995)
27. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.